The Wealth of Nations during the Pandemic: The Vaccine Equity

Basit Öğe Kaydı
dc.authoridShahbaz, Muhammad/0000-0003-4916-7648en_US
dc.authorwosidGedikli, Ayfer/KFB-6037-2024en_US
dc.authorwosidShahbaz, Muhammad/AAD-9038-2019en_US
dc.contributor.authorGedikli, Ayfer
dc.contributor.authorErdogan, Seyfettin
dc.contributor.authorShahbaz, Muhammad
dc.date.accessioned2024-08-23T16:03:51Z
dc.date.available2024-08-23T16:03:51Z
dc.date.issued2022en_US
dc.departmentDüzce Üniversitesien_US
dc.description.abstractAggressive global dissemination of the coronavirus indicated the urgency of the development of vaccines at an unprecedented rate and scale. The limited production and short supply of vaccines which were reserved mostly for the advanced economies were the greatest problems of 2021. For emerging economies, this timeline will stretch to late 2022 or early 2023. As a part of systematic immunization programs, the development, licensing, and implementation of the vaccines against the Covid-19 virus started to address health service inequalities among countries. While on one hand vaccination is regarded to be one of the most cost-effective interventions in public health during the pandemic, on the other hand, the introduction and sustainable supply of vaccines needed to be supported and ensured by decision-makers and governments. Due to the weak economic conditions of developing countries, they could not provide enough financial and health support to their citizens during this period. However, since the global GDP loss from not inoculating all countries is higher than the cost of manufacturing and distributing vaccines globally, there has been a growing demand to international cooperation to have global vaccination without omitting any countries. This paper focuses on the economic and social costs and benefits of vaccinations during the Covid-19 pandemic period in advanced, middle, and low-income countries. Accordingly, macroeconomic and social impacts of vaccination will be discussed and some policy suggestions will be put forth to get more benefits from the vaccination both for economic and health outcomes.en_US
dc.identifier.doi10.18521/ktd.1106860
dc.identifier.endpage182en_US
dc.identifier.issn1309-3878
dc.identifier.startpage172en_US
dc.identifier.urihttps://doi.org/10.18521/ktd.1106860
dc.identifier.urihttps://hdl.handle.net/20.500.12684/13946
dc.identifier.volume14en_US
dc.identifier.wosWOS:001014567800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherDuzce Univ, Fac Medicineen_US
dc.relation.ispartofKonuralp Tıp Dergisi
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19 Pandemicen_US
dc.subjectVaccineen_US
dc.subjectDeveloping Countriesen_US
dc.subjectMiddle-Income Countriesen_US
dc.titleThe Wealth of Nations during the Pandemic: The Vaccine Equityen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Konuralp Tip Dergisi Koleksiyonu